Absci (ABSI) H.C. Wainwright 26th Annual Global Investment Conference summary

Generative AI and platform capabilities

• Generative AI is used to design differentiated protein therapeutics by integrating high-throughput data generation and model validation, focusing on understanding protein-protein interactions at the epitope level.

• The Integrated Drug Creation platform enables epitope-specific antibody engineering, AI-driven optimization for clinical features, and significant efficiency gains, reducing candidate development timelines to 12 months.

Differentiation and validation

• Zero-shot generative AI enables de novo antibody design, validated by third-party milestones, such as rapid antibody generation for AstraZeneca's difficult targets.

• Proprietary engineered E. coli allows high-throughput functional screening and validation, bridging computational design and lab testing.

Partnerships and collaborations

• Recent collaborations include AstraZeneca, Almirall, PrecisionLife, and Memorial Sloan Kettering, with technical milestones achieved and up to six co-development programs planned with MSK.

• Guidance for 2024 includes at least four new partnerships, with more announcements expected by year-end.